

Atty. Docket No.: LeA 35 944

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Stefan Golz, *et al.*

SERIAL NO.: [to be assigned] National Stage filing for PCT/EP03/02685

FILING DATE: herewith

TITLE: Diagnostics and Therapeutics for Diseases Associated with Neuropeptide FF Receptor 1 (NPFF1)

---

**PRELIMINARY AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Preliminary Amendment is submitted in the above-captioned application. Please amend the application as follows:

**In the Claims**

Please amend claims 1-12 and 18-26 as shown in the attached sheets (pages 3-7 of this amendment).

**Remarks**

By way of this Preliminary Amendment, claims 1-26 are pending. Claims 1-12 and 18-26 have been amended. These claim cancellations and amendments are being made solely for purposes of placing the claims in a format appropriate for U.S. prosecution. Applicants submit that the amendments do not change the scope of the claims as originally filed. Such amendments are therefore made to address formalities in the claim format and are not related to the patentability of the subject matter of the claims. No new matter was added by way of these claim amendments and additions.